Clinical Trials

3D-PREDICT REGISTRY: 3D Prediction of patient-specific response using ex vivo interrogation of live cells from tumors

• Study Information: NCT03561207 (https://clinicaltrials.gov/ct2/show/NCT03561207)
• Sponsor: KIYATEC, Inc.
• Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
• Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery

• Study Information: NCT03180268 (https://clinicaltrials.gov/ct2/show/NCT03180268)
• Sponsor: National Clinical Trials Network, NCI through collaborative groups
• Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
• Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Molecular and biochemical characterization of malignant and metastatic brain tumors

• Study Information: NCT N/A
• Sponsor: Capital Health System, Inc. in collaboration with Princeton University and Rutgers University
• Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
• Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Genomically-guided treatment trial in brain metastasis

• Study Information: NCT03994796 (https://clinicaltrials.gov/ct2/show/NCT03994796)
• Sponsor: National Clinical Trials Network, NCI through collaborative groups
• Principal Investigator: Dr. Neel Gandhi, Medical Oncologist
• Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Assessing quality of life in adult neuro-oncology patients after Cyberknife or WBRT (Whole Brain Radiation Therapy), a prospective registry

• Study Information: NCT N/A
• Sponsor: Capital Health System, Inc.
• Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
• Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

The use of the ketogenic diet as an adjuvant to treatment of glioblastome multiforme

• Study Information: NCT N/A
• Sponsor: Capital Health System, Inc.
• Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
• Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Randomized, phase III trial evaluating the role of weight loss in adjuvant treatment of overweight women with early breast cancer (BWEL)

• Study Information: NCT02750826 (https://clinicaltrials.gov/ct2/show/NCT02750826)
• Sponsor: National Clinical Trials Network, NCI through collaborative groups
• Principal Investigator: Rose Mustafa, MD, Breast Oncologic Surgeon
• Contact: Shannon David, RN, Clinical Research Coordinator at [email protected] or 609-394-4733

Registry to evaluate effectiveness and safety of the Nanoknife system for the ablation of stage 3 pancreatic cancer – DIRECT

• Study Information: NCT03899649 (https://clinicaltrials.gov/ct2/show/NCT03899649)
• Sponsor: Angiodynamics, Inc.
• Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Surgeon, Medical Director Cancer Center
• Contact: Dr. Soraya Sanchez-Molero, Clinical Research Coordinator at [email protected] or 609-537-6014

Circulating Biomarkers and Cancer

• Study Information: NCT N/A
• Sponsor: Capital Health System, Inc. in collaboration with the Blumberg Institute, PA
• Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Surgeon, Medical Director Cancer Center
• Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042

A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers

• Study Information: NCT04251052 (https://clinicaltrials.gov/ct2/show/NCT04251052)
• Sponsor: National Clinical Trials Network, NCI through collaborative groups
• Principal Investigator: Joyce Varughese, MD, FACOG, GYN Oncologic Surgeon
• Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042

A randomized phase III trial of induction/consolidation Atezolizumab + SBRT Versus SBRT alone in high risk, early stage NSCLC

• Study Information: NCT0421462 (https://clinicaltrials.gov/ct2/show/NCT04214262)
• Sponsor: National Clinical Trials Network, NCI through collaborative groups
• Principal Investigator: Shirnett Williamson, MD, Radiation Oncologist
• Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

NCI-MATCH: Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma

• Study Information: NCT02465060 (https://clinicaltrials.gov/ct2/show/NCT02465060)
• Sponsor: National Clinical Trials Network, NCI through collaborative groups
• Principal Investigator: David Schaebler, MD, Medical Oncologist
• Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042

Cancer Tissue Biorepository

• Study Information: NCT N/A
• Sponsor: Capital Health System, Inc.
• Principal Investigator: Krister Jones, MD, Pathologist
• Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042